Last updated: February 13, 2026
What Is the Market Status of the Drug NDC 00143-9398?
NDC 00143-9398 corresponds to a generic formulation of dexamethasone, a corticosteroid used to treat inflammation, allergic reactions, and certain diseases affecting the immune system. The drug competes primarily in the generic corticosteroid segment, with broad applications across hospitals, clinics, and outpatient settings.
Market Overview
- Product Class: Dexamethasone; corticosteroid.
- Approvals: Widely approved across the US for indications such as inflammatory conditions, certain cancers, and COVID-19 management.
- Manufacturers: Multiple pharmaceutical companies produce generic dexamethasone, including Teva, Sandoz, and Mylan.
- Market Size: The US corticosteroids market was valued at approximately $1.2 billion in 2022; dexamethasone constitutes roughly 25-30% of that segment, i.e., around $300 million.
Market Dynamics
- Demand Drivers: The drug's involvement in COVID-19 treatment protocols has temporarily increased demand; however, this volume decline is expected as protocols evolve.
- Competitive Landscape: Several generics compete on price, with recent entrants pushing prices downward.
- Regulatory Status: No major patents restrict market entry for generic versions; expected patent expirations for brand equivalents occurred around 2010–2015, facilitating broad generic competition.
- Healthcare Trends: Increased outpatient use and hospital protocols sustain steady demand; shortages or supply disruptions could temporarily influence prices.
What Are the Price Projections for NDC 00143-9398?
Current Pricing
- Average Wholesale Price (AWP): ~$0.10–$0.15 per 4 mg/mL vial (as of Q1 2023).
- Acquisition Cost: Pharmacies and hospitals purchase at approximately 15–30% below AWP, typically around $0.07–$0.12 per vial.
- Reimbursement Rates: Vary depending on insurance and procurement contracts; Medicare Part B reimburses approximately 80% of the average sales price.
Short-Term Price Projections (Next 1–2 Years)
- Prices are expected to stabilize within current ranges unless supply chain issues arise.
- Slight downward pressure expected, driven by increased generic competition and price erosion.
- No significant price inflation anticipated unless supply disruptions occur.
Long-Term Price Trends (3–5 Years)
- Prices may decline progressively by 10–20% as more generic manufacturers increase production volumes.
- Market saturation could further compress margins.
- External factors such as regulatory changes, manufacturing costs, or shifts in treatment protocols could influence prices variably.
Comparative Data
| Factor |
Current Price Range |
Price Trend |
| Wholesale acquisition cost |
$0.07–$0.12 per vial |
Steady with slight downward trend |
| Hospital procurement price |
Similar to AWP |
Slight decrease expected |
| Insurance reimbursement rate |
~80% of sales price |
Remains consistent |
How Do These Projections Compare to Similar Drugs?
- Dexamethasone prices tend to decline analogously with other corticosteroids like hydrocortisone and prednisone, which have seen 10–15% price reductions over the past five years.
- The savings are primarily driven by increased market entries and manufacturing efficiencies.
What Regulatory or Market Changes Could Affect Future Prices?
- Patent expirations open market access, but for NDC 00143-9398, patents expired several years ago.
- Potential drug shortages could temporarily increase prices. Recent shortages in corticosteroids are rare but have occurred occasionally due to manufacturing issues.
- Legislative measures aimed at drug price transparency or further generic competition could put continued downward pressure on prices.
Summary
NDC 00143-9398 is a generic dexamethasone formulation with a broad, mature market. Prices are stable but trending downward due to intense generic competition. Short-term prices are unlikely to change significantly unless supply issues or regulatory shifts occur. Long-term expectations include gradual price declines driven by increased production efficiency and market saturation.
Key Takeaways
- The drug’s market is mature, with multiple producers contributing to price competition.
- Current wholesale prices range from $0.07 to $0.12 per vial.
- Expect modest price erosion over the next five years, with potential short-term increases amid supply disruptions.
- Demand remains stable; seasonal and institutional factors govern fluctuations.
- Regulatory changes are unlikely to significantly alter pricing trajectories unless policy initiatives target the generic corticosteroid segment.
FAQs
1. Why is dexamethasone priced so low compared to other corticosteroids?
Due to patent expirations and extensive generic competition, dexamethasone's manufacturing costs have decreased, and supply is abundant, driving prices down.
2. Will the demand for NDC 00143-9398 increase with ongoing COVID-19 treatments?
Initial COVID-19 treatment protocols boosted demand temporarily; however, since corticosteroids like dexamethasone are now standard, demand remains steady rather than increasing significantly.
3. Are there any patent or exclusivity issues affecting this drug?
Patents for dexamethasone expired years before 2023, enabling generic manufacturers to produce and market the drug freely.
4. How does the regulatory environment influence price projections?
The absence of patent protections and regulatory barriers means market forces primarily drive prices, leading to a trend of gradual decrease over time.
5. Could new formulations or delivery methods disrupt the current price trend?
New formulations or delivery systems could command higher prices initially; however, standard formulations like NDC 00143-9398 are likely to follow prevailing market prices unless significant clinical advantages are demonstrated.
[1] United States Food and Drug Administration (FDA). "Approved Drug Products with Therapeutic Equivalence Evaluations," 2022.
[2] IQVIA. "Pharmaceutical Market Data," 2022.
[3] Bloomberg Industry Data. "Generic Drugs Pricing," 2023.
[4] Medicare Reimbursement Policies. CMS, 2023.
